Lexington Medical, Inc.
$96.2K 119 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Thrombolex, Inc.
Thrombolex, Inc. reported $96,575.26 across General Payments, Research, and Ownership to 232 physicians and teaching hospitals across 234 transactions.
- $96.6K Below-median payer
- All-tracks total
- 234 Above-median volume
- Transactions
- 232 Above-median reach
- Recipients
- +$7.5K
- General Payments vs PY2023
Thrombolex, Inc. reported $96,575.26 across all CMS Open Payments tracks (General + Research + Ownership) to 232 physicians and teaching hospitals in Program Year 2024 - ranking #1193 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $11,129.26, averaging $416.27 per recipient.
How Thrombolex, Inc.'s $96.6K all-tracks total breaks down
Thrombolex, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
15/100
Total payments
F
11/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer thrombolex-inc Thrombolex, Inc.
$96.6K · #1193/1,925 · 0.0% industry · PY2024
- TOT $96.6K
- RANK #1193
- SHARE 0.0%
- TXN 234
- RCP 232
- CAT 2
- GEN $11.1K
- ΔGEN +$7.5K
- TOP1 4.9%
- PY 2024
Volume peers
Nearest volume peer: Lexington Medical, Inc. ($96.2K)
Thrombolex, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Thrombolex, Inc.'s CMS-reported General Payments increased by $7.5K (+208.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: THROMBOLEX, INC.PY2024: Thrombolex, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $3,612.50
- PY2024
- $11,129.26
What the Data Shows for Thrombolex, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Thrombolex, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $11.1K, accounting for 99.9% of this company's General Payments and 231 transactions.
General Payment Breakdown by Type
Thrombolex, Inc. made 2 types of general payments. "Food and Beverage" is the largest category at $11.1K, 99.9% of General Payments.
How Thrombolex, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $11.1K | 231 | 99.9% |
| Charitable Contribution | $15.81 | 1 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,843.70 (16.6%) of $11,129.26 in this company's General Payments records across 195 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Thrombolex, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Eric Gnall
$540.00 across 1 reported transactions
- 2
Jorge Carlos Magallon
$532.96 across 2 reported transactions
- 3
Michael Levy
$278.67 across 2 reported transactions
- 4
Chad Christopherson
$266.48 across 1 reported transactions
- 5
Murtaza Mazhar
$225.59 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Thrombolex, Inc. ranks #1193 of 1,925 by total payments (bottom 38% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,631 of 1,838 by HHI (bottom 11% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Smith+Nephew, Inc. : $46.4M total payments, HHI 151
- Dendreon Pharmaceuticals LLC : $659.8K total payments, HHI 150
- Aimmune Therapeutics, Inc. : $2.1M total payments, HHI 149
- Insmed, Inc. : $1.1M total payments, HHI 148
- Ermi LLC : $10.5K total payments, HHI 145
- Vertos Medical, Inc. : $796.2K total payments, HHI 142
- Thrombolex, Inc. (this company) : $11.1K total payments, HHI 142
- Scpharmaceuticals Inc. : $980.4K total payments, HHI 141
- Mannkind Corporation : $423.2K total payments, HHI 141
- Hill Dermaceuticals, Inc. : $15.7K total payments, HHI 140
- Axogen : $1.8M total payments, HHI 139
- Johnson and Johnson International : $11.1K total payments, HHI 138
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Thrombolex, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Thrombolex, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Thrombolex, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Suvon Surgical Llc
$96.2K 650 recipients
Compare payment profiles
Elite Orthopedics, Llc
$97.1K 1,176 recipients
Compare payment profiles
Podimetrics, Inc.
$97.6K 12 recipients
Compare payment profiles
Microsurgical Technology, Inc.
$97.7K 124 recipients
Compare payment profiles
Moximed, Inc
$95.5K 48 recipients
Compare payment profiles
Put this to use
Thrombolex, Inc. ranks #1193 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Thrombolex, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.